Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder. Definium Therapeutics applies a research-driven approach to psychedelic-derived and other brain-health-focused therapeutics, aiming to address underlying causes of psychiatric and neurological conditions. The company operates from New York and serves the healthcare and biotechnology markets through its drug development programs and clinical research activities.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$354M
▼ -69.1% YoY
Op. Margin
–
ROIC
-41.30%
▼ -10.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$168M
▼ -66.3% YoY
Op. Cash Flow (TTM)
-$168M
▼ -66.3% YoY
Net Debt
-$371M
Net Cash Position
Cash & Equiv.
$412M
Continue Research
Peers
Biotechnology · Pick stocks to compare with DFTX
Held by ETFs
DFTX is in 50 US ETFs. The largest of them, with DFTX's weight in each:
Definium Therapeutics (DFTX) in three numbers
Questions about Definium Therapeutics
Is Definium Therapeutics a high-quality business?
Definium Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$371M, and its weakest is return on capital at -41.3%. The Quality tab shows every check against its target.
Does Definium Therapeutics (DFTX) pay a dividend?
No. Definium Therapeutics (DFTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DFTX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.